LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

54.48 -0.58

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

53.83

Max

54.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.7M

-100M

Pardavimai

29M

232M

Pelno marža

-43.044

Darbuotojai

1,999

EBITDA

22M

-89M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+14.15% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2B

7.5B

Ankstesnė atidarymo kaina

55.06

Ankstesnė uždarymo kaina

54.48

Naujienos nuotaikos

By Acuity

17%

83%

25 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-12 22:41; UTC

Pagrindinės rinkos jėgos

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025-09-12 16:04; UTC

Pagrindinės rinkos jėgos

Upexi Shares Climb on Solana Gains

2025-09-14 23:48; UTC

Rinkos pokalbiai

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025-09-14 23:41; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025-09-14 23:38; UTC

Rinkos pokalbiai

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-14 23:04; UTC

Rinkos pokalbiai

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025-09-13 08:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-09-12 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-09-12 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-12 20:09; UTC

Uždarbis

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025-09-12 19:23; UTC

Rinkos pokalbiai

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025-09-12 19:16; UTC

Rinkos pokalbiai

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025-09-12 19:03; UTC

Rinkos pokalbiai

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025-09-12 18:59; UTC

Rinkos pokalbiai

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025-09-12 18:38; UTC

Rinkos pokalbiai
Uždarbis

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025-09-12 18:33; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025-09-12 18:22; UTC

Rinkos pokalbiai

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025-09-12 16:56; UTC

Rinkos pokalbiai

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025-09-12 16:22; UTC

Uždarbis

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025-09-12 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-12 16:19; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025-09-12 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-12 16:11; UTC

Uždarbis

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025-09-12 15:37; UTC

Rinkos pokalbiai

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025-09-12 15:22; UTC

Rinkos pokalbiai

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025-09-12 15:07; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

14.15% į viršų

12 mėnesių prognozė

Vidutinis 62.67 USD  14.15%

Aukščiausias 70 USD

Žemiausias 56 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

14

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

25 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat